33 results
424B3
PRTG
Portage Biotech Inc
28 Feb 24
Prospectus supplement
5:19pm
resistance and expanding the addressable patient population. Given these foundations, we manage capital allocation and risk as much as we oversee drug
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Feb 24
Current report (foreign)
5:17pm
manage capital allocation and risk as much as we oversee drug development. By focusing our efforts on translational medicine and pipeline diversification
424B3
PRTG
Portage Biotech Inc
28 Nov 23
Prospectus supplement
4:03pm
manage capital allocation and risk as much as we oversee drug development. By focusing our efforts on translational medicine and pipeline
6-K
EX-99.2
PRTG
Portage Biotech Inc
28 Nov 23
Current report (foreign)
4:01pm
resistance and expanding the addressable patient population. Given these foundations, we manage capital allocation and risk as much as we oversee drug
424B3
PRTG
Portage Biotech Inc
7 Nov 23
Prospectus supplement
4:50pm
as much as we oversee drug development. By focusing our efforts on translational medicine and pipeline diversification, we seek to mitigate overall
F-1
rzl372
31 Oct 23
Registration statement (foreign)
4:05pm
424B5
6ri9557
2 Oct 23
Prospectus supplement for primary offering
6:01pm
6-K
EX-99.2
p55xjho5c0xzlue8kxy
29 Aug 23
Current report (foreign)
4:01pm
6-K
EX-99.2
ivaljf1q
29 Nov 22
Current report (foreign)
4:58pm
6-K
EX-99.2
mej4ac
29 Aug 22
Current report (foreign)
4:00pm
424B5
4thqafzg41hcg4ztm3
19 Aug 22
Prospectus supplement for primary offering
10:52am
6-K
EX-99.2
qi3ii s36oi4
25 Feb 22
Current report (foreign)
5:29pm
6-K
EX-99.2
5qkiieal509 dy
23 Nov 21
Current report (foreign)
4:30pm
6-K
EX-99.2
2a8k edc844cl
30 Aug 21
Current report (foreign)
5:21pm